DNQX
DNQX is a competitive antagonist of the AMPA receptor, a type of ionotropic glutamate receptor. It is commonly used in research to help understand the function of these receptors, and has also been used in the study of neurodegenerative diseases and conditions such as epilepsy and ischemia.
Chemistry[edit]
DNQX, or 6,7-dinitroquinoxaline-2,3-dione, is a quinoxalinedione compound. It is a yellow solid at room temperature. It is soluble in DMSO and ethanol, but not in water.
Mechanism of action[edit]
DNQX acts as a competitive antagonist at the AMPA receptor, meaning it binds to the same site as the natural ligand, glutamate, but does not activate the receptor. This prevents glutamate from binding and activating the receptor, effectively blocking the receptor's function.
Uses in research[edit]
DNQX is commonly used in neuroscience research to help understand the function of AMPA receptors. By blocking these receptors, researchers can study their role in various processes in the nervous system.
In addition, DNQX has been used in the study of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. It has also been used in research on conditions such as epilepsy and ischemia, where overactivation of glutamate receptors can lead to cell death.
Safety[edit]
As with any chemical, DNQX should be handled with care. It can cause eye, skin, and respiratory irritation. It is not intended for human consumption.
See also[edit]
References[edit]
External links[edit]
DNQX[edit]
-
DNQX
-
DNQX molecule spacefill
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
